Scarica l'app Stockscreener
7.22
4.49%
0.31
Dopo l'orario di chiusura:
7.22
Precedente Chiudi:
$6.91
Aprire:
$6.595
Volume 24 ore:
59,372
Relative Volume:
1.79
Capitalizzazione di mercato:
$141.02M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-4.75%
1M Prestazione:
+10.91%
6M Prestazione:
+3.03%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$6.35
$7.31
Intervallo di 1 settimana:
$6.10
$7.975
Portata 52W:
$5.51
$11.73
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Nome
Actuate Therapeutics Inc
Settore
Industria
Telefono
847-986-4190
Indirizzo
1751 RIVER RUN, FORT WORTH
Confronta ACTU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
7.22 | 141.02M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-17 | Iniziato | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Borsa (ACTU) Ultime notizie
Soft Tissue Sarcoma with Lung Metastases Treatment Market Size - openPR.com
Bone Metastasis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight - Barchart.com
Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews
Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc - Marketscreener.com
Actuate Therapeutics Files Prospectus To Offer, Sale Of Up To 3.9 Million Shares By B. Riley Principal Capital II, LLC - MarketScreener
Growth Driver In The Locally Advanced Pancreatic Cancer Market 2 - News Channel Nebraska Southeast
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer (NASDAQ:ACTU) - Seeking Alpha
Brokers Set Expectations for ACTU Q1 Earnings - Defense World
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR.com
WIN Consortium leading the future of precision cancer medicine - EurekAlert
Actuate Therapeutics (NASDAQ:ACTU) Now Covered by HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Actuate Therapeutics (ACTU) with Buy Recommendation - Nasdaq
Actuate Therapeutics: Promising Phase 2 Results and Market Potential for Elraglusib in Metastatic Pancreatic Cancer - TipRanks
Actuate Therapeutics Inc. (ACTU) reports earnings - Quartz
ACTUATE THERAPEUTICS, INC. SEC 10-K Report - TradingView
Pre-market Movers: AWH, TSVT, CUTR, SNOA... - RTTNews
Neuroblastoma Pipeline 2025: Key Companies, MOA, ROA, - openPR
Ratio Chart Of U.S. Dollar Index Against 10Y U.S. Notes Is Pointing Much Lower - The Globe and Mail
Zoom Stock: Leading the Video Market After Skype’s Exit - The Globe and Mail
Pancreatic And Bile Duct Cancer Drug Market Enhancing Cybersecurity and Cloud Integration for the Future - ExpressVartha
Actuate reports progress in pancreatic cancer trial By Investing.com - Investing.com Australia
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
Candel reports extended survival in Phase II CAN-2409 trial - The Pharma Letter
Actuate Announces Completion of Enrollment in a Phase 2 - GlobeNewswire
Actuate reports progress in pancreatic cancer trial - Investing.com India
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer - Yahoo Finance
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February - Marketscreener.com
Adenoid Cystic Carcinoma Market: Analysis of Epidemiology, - openPR
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public - BioPharma Dive
Pancreatic Adenocarcinoma Market Growth Projections - openPR
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Invest In Growth? - simplywall.st
Actuate Therapeutics sets annual meeting for May 22 - MSN
How To Work With Trump, The Future Of US Life Sciences And More: Updates From BIO CEO & Investor - Scrip
Actuate Therapeutics' IPO Lock-up Period Expires Today - RTTNews
Certain Restricted Stock Units of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Certain Stock Options of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Certain Common Stock of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Actuate Therapeutics, Inc. to Hold Annual Meeting of Stockholders on May 22, 2025 - Armenian Reporter
Invesco BulletShares 2019 Corporate Bond ETF (NYSEARCA:BSCJ) Stock Price Down 0% – Here’s Why - Armenian Reporter
Actuate Therapeutics sets annual meeting for May 22 By Investing.com - Investing.com UK
Matrix Service (NASDAQ:MTRX) Posts Earnings Results, Beats Expectations By $0.02 EPS - Armenian Reporter
Actuate Therapeutics' Lock-Up Period Will Expire on February 10th (NASDAQ:ACTU) - MarketBeat
Ataxia Telangiectasia Market on Track for Major Expansion by 2032, According to DelveInsight | Acasti Pharma Inc., IntraBio Inc - The Globe and Mail
Actuate Therapeutics’ (NASDAQ:ACTU) Lock-Up Period Set To Expire on February 10th - Defense World
Alterity surges after mid-stage trial data for lead asset - MSN
Actuate Therapeutics (NASDAQ:ACTU) Trading Down 5.4%Here's What Happened - MarketBeat
Actuate Therapeutics Inc Azioni (ACTU) Dati Finanziari
Non sono disponibili dati finanziari per Actuate Therapeutics Inc (ACTU). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):